Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1902-1911

  Chraybi, Meriem ^a   Alsamad, Issam Abd ^a   Copie Bergman, Christiane ^b   Baia, Maryse ^b   André, Jocelyne ^c   Dumaz, Nicolas ^c   Ortonne, Nicolas ^b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

BRAF mutation; CCND1 amplification; Cyclin D1; KIT; NRAS; Primary malignant melanoma of sinonasal tract; Sinonasal melanoma

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MDM2; PROTEIN S 100; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MELANOMA; ONCOGENE N RAS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SPINDLE CELL;

BRAF MUTATION; CCND1 AMPLIFICATION; CYCLIN D1; KIT; NRAS; PRIMARY MALIGNANT MELANOMA OF SINONASAL TRACT; SINONASAL MELANOMA;

AGED; AGED, 80 AND OVER; CYCLIN D1; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PARANASAL SINUS NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES;

EID: 84883465248     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.01.025     Document Type: Article

References (14)

1. L.D. Thompson, J.A. Wieneke, and M. Miettinen Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system Am J Surg Pathol 27 2003 594 611
2. M.L. Prasad, S.G. Patel, A.G. Huvos, J.P. Shah, and K.J. Busam Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors Cancer 100 2004 1657 1664
3. M.A. Davies, and Y. Samuels Analysis of the genome to personalize therapy for melanoma Oncogene 29 2010 5545 5555
4. C.A. Torres-Cabala, W.L. Wang, and J. Trent Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type Mod Pathol 22 2009 1446 1456
5. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
6. J. Guo, L. Si, and Y. Kong Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Oncol 29 2011 2904 2909
7. M. Turri-Zanoni, D. Medicina, and D. Lombardi Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases Head Neck 2012 [Epub ahead of print]
8. K.S. Smalley, M. Xiao, and J. Villanueva CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations Oncogene 28 2009 85 94
9. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
10. I.A. Prior, P.D. Lewis, and C. Mattos A comprehensive survey of Ras mutations in cancer Cancer 72 2012 2457 2467
11. V.T. Tormanen, and G.P. Pfeifer Mapping of UV photoproducts within ras proto-oncogenes in UV-irradiated cells: correlation with mutations in human skin cancer Oncogene 7 1992 1729 1736
12. B.S. Jaiswal, V. Janakiraman, and N.M. Kljavin Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors PLoS One 4 2009 e5717
13. A. Marquette, J. Andre, M. Bagot, A. Bensussan, and N. Dumaz ERK and PDE4 cooperate to induce RAF isoform switching in melanoma Nature 18 2011 584 591
14. Y. Kong, L. Si, and Y. Zhu Large-scale analysis of KIT aberrations in Chinese patients with melanoma Clin Cancer Res 17 2011 1684 1691